Skip navigation

DSpace JSPUI

DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets

Learn More
DSpace logo
English
中文
  • Browse
    • Communities
      & Collections
    • Publication Year
    • Author
    • Title
    • Subject
  • Search TDR
  • Rights Q&A
  • Help
    • My Page
    • Receive email
      updates
    • Edit Profile
  1. NTU Theses and Dissertations Repository
  2. 生物資源暨農學院
  3. 農藝學系
Please use this identifier to cite or link to this item: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47978
Title: 羅吉斯回歸於生物相似性藥品對等性評估之應用
On Study of Applications of the Logistic Regression to Evaluation of Equivalence of Similar Biological Medicinal Products
Authors: Chih-Hsi Chang
張志熙
Advisor: 劉仁沛(Jen-Pei Liu)
Keyword: Biological products,Biosimilar,Logistic regression,
生物製劑,生物製劑相似性藥品,羅吉斯回歸,
Publication Year : 2011
Degree: 碩士
Abstract: 生物製劑的市場近年來逐漸增加,但是所需的開發成本仍然很高,所以在生物製劑的專利到期以後,許多藥廠紛紛投入生物相似性藥品的研發。不同於一般的化學分子學名藥,生物製劑具有製程專一的特性,所以評估生物相似性藥品必須與化學分子學名藥有所不同。現行法規中,生物相似性藥品需依個案,適度的減免臨床試驗,才能被核准上市,成本並不小於開發新的生物製劑,無法降低成本,達到造福病患之目的。
當療效指標為二元變數時,本篇論文以羅吉斯回歸檢定法評估生物製劑相似性藥品與原廠生物製劑是否有差異,以評估是否需要執行完整臨床試驗,模擬所提出方法之第一型錯誤機率、檢定力和覆蓋率,並以數值例子來介紹方法之應用。
In recent years, biologics market increases rapidly, but the development costs are also very high. Therefore, after the patent of biological products expires, many pharmaceutical companies have invested in the development of biosimilar products. But, biological products, with process specificity, are different from traditional small molecule drug products. Thought the methods for assessment of biosimilar products are also different. Current regulations indicate that the clinical trials for assessment can be waived on a case-by-case basis, but a pharmacovigilance is necessary. However, if the requirement for clinical trials cannot be waived, the development cost of biosimilar products will be the same as that of the innovators, and it cannot achieve the goal of cost reduction.
In this thesis, we try to apply the logistic regression to test whether the approval of the biosimilar should require clinical trials and to evaluate the similarity between the biosimilar products and innovator’s biological products when the primary endpoint as a binary variable. The results of size and power from the simulation studies are presented. A numerical example is used to illustrate the application of the proposed method.
URI: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47978
Fulltext Rights: 有償授權
Appears in Collections:農藝學系

Files in This Item:
File SizeFormat 
ntu-100-1.pdf
  Restricted Access
1.09 MBAdobe PDF
Show full item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved